financetom
Business
financetom
/
Business
/
Capricor Therapeutics Receives FDA's Acceptance for Review of BLA for Duchenne Muscular Dystrophy Treatment
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Capricor Therapeutics Receives FDA's Acceptance for Review of BLA for Duchenne Muscular Dystrophy Treatment
Mar 4, 2025 5:50 AM

08:19 AM EST, 03/04/2025 (MT Newswires) -- Capricor Therapeutics ( CAPR ) said Tuesday it has received the US Food and Drug Administration's acceptance for review of its biologics license application for full approval of deramiocel to treat Duchenne muscular dystrophy cardiomyopathy.

The regulator's decision was based on the company's current cardiac data from its phase 2 HOPE-2 and HOPE-2 open label extension studies, Capricor added.

The regulator set Aug. 31 as the Prescription Drug User Fee Act target action date without any potential review issues at the moment, the company said.

Capricor's stock rose nearly 12% in recent Tuesday premarket activity.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Copyright 2023-2026 - www.financetom.com All Rights Reserved